2. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. с соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучениюпечени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 26(2): 24–42.

3. Marchesini G., Day Ch.P., Dufour J.F. et al. EASL-EASD-EASO Clinical Practice Guidelinesfor the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388–402. doi:10.1016/j.jhep.2015.11.004.

4. Moschetta A., Modica S., Gadaleta R.M. Modulation of nuclear bile acid receptor FXR activity inthe gut – liver axis. Nucl Recept Signal. 2010: 8: S005.

5. Bedossa P. Current histological classification of NAFLD: strength and limitations. Hepatol Int. 2013;7 (Suppl. 2): 765–70. doi: 10.1007/s12072-013-9446-z.

6. Маммаев С.Н., Багомедова Н.В., Богомолов П.О. с соавт. Цитокиновая система при неалкогольном стеатогепатите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007; 17(4): 30–35.

7. Ikura Y. Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease duringthe last three decades. Wld J Hepatol. 2014; 12(6): 894–900. doi: 10.4254/wjh.v6.i12.894.

8. Маевская М.В., Буеверов А.О. Лечение алкогольной болезни печени. Под ред. акад.Ивашкина В.Т. Методические рекомендации для врачей. М.: Планида., 2011; 24 с.

9. Маевская М.В., Морозова М.А., Ивашкин В.Т. Алгоритм ведения пациентов с алкогольнойболезнью печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии.2011; 21(1): 4–10.

10.Pavlov C.S., Casazza G., Pavlova M. et al. Ultrasonography for diagnosis of cirrhosis in people withalcoholic liver disease. Cochrane Database Syst Rev. 2016; 3: CD011602. doi: 10.1002/14651858.CD011602.

11.Mechanick J.I., Kushner R.F., Sugerman H.J. et al. American Association of ClinicalEndocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric SurgeryMedical Guidelines for Clinical Practice for the perioperative nutritional, metabolic, and nonsurgicalsupport of the bariatric surgery patient.. Surg Obes Relat Dis. 2008; 4 (Suppl 5): S109–84. doi:10.1016/j.soard.2008.08.009.

12. Sanyal A.J., Chalasani N., Kowdley K.V. et al. Pioglitazone, vitamin E, or placebo for nonalcoholicsteatohepatitis. N Engl J Med. 2010; 362: 1675–85. doi: 10.1056/NEJMoa0907929.

13.Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J. et al. A placebo-controlled trialof pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006; 355: 2297–307.

14.Aithal G.P., Thomas J.A., Kaye P.V. et al. Randomized, placebo-controlled trial of pioglitazone innondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008; 135: 1176–84. doi:10.1053/j.gastro.2008.06.047.

15.Armstrong M.J., Gaunt P., Aithal G.P. et al. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebocontrolled phase2 study. Lancet. 2016; 387(10019): 679–90. doi: 10.1016/S0140-6736(15)00803-X.

16. Dongiovanni P., Petta S., Mannisto V. et al. Statin use and nonalcoholic steatohepatitis in at riskindividuals. J Hepatol. 2015; 63: 705–12. doi: 10.1016/j.jhep.2015.05.006.

17.Kostapanos M.S., Kei A., Eliasaf M.S. Current role of fenofibrate in the prevention and managementof nonalcoholic fatty liver disease. Wld J Hepatol. 2013; 5(9): 470–78. doi: 10.4254/wjh.v5.i9.470.

18.Parker H.M., Johnson N.A., Burdon C.A. et al. Omega-3 supplementation and non-alcoholic fattyliver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944–51. doi: 10.1016/j.jhep.2011.08.018.

19. Li Z., Agellon L.B., Allen T.M. et al. The ratio of phosphatidylcholine to phosphatidylethanolamineinfluences membrane integrity and steatohepatitis. Cell Metab. 2006; 3: 321–31.

20. Virukalpattigopalratnam M.P., Singh T., Ravishankar A.C. Heptral (ademetionine) in patientswith intrahepatic cholestasis in chronic liver disease due to non-alcoholic liver disease: results of amulticentre observational study in India. J Indian Med Assoc. 2013; 111(12): 856–59.

21. Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease:A field trial. Current Therapeutic Research. 1999; 60(6): 335–348.

22.Ratziu V. et al. A proposal for current and future therapeutic strategies for NASH. EASL SpecialConference «NAFLD/NASH and Related Metabolic Disease». Bologna, Italy, 2009. Program andAbstracts. P. 29.

23.Mueller M., Thorrel A., Claudel T. et al. Ursodeoxycholic acid exerts farnesoid Xreceptorantagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol. 2015;62(6): 1398–404. doi: 10.1016/j.jhep.2014.12.034.

24. Sas E., Grinevich V., Efimov O. et al. Beneficial influence of polyunsaturated phosphatidylcholineenhances functional liver condition and liver structure in patients with Nonalcoholic steatohepatitis.Results of prolonged randomized blinded prospective clinical study. J Hepatol. 2013; 58: S549. doi:10.1016/S0168-8278(13)61365-3.

25. Dajani Al., Abu Hammour A.M., Zakaria M.A. et al. EPL in themanagement of primary NAFLD andNAFLD associated with co-morbid disease. Hepatol Int. 2013; 7(Suppl 1): S108.

26. Un C., Zheng X., Tan Z. et al. Clinical observation on polyene phosphatidyl choline and metforminin the treatment of type 2 diabetes and non-alcoholic fatty liver disease. Clin Focus. 2008; 23(17):1272–73.

27. Haddad Y., Vallerand D., Brault A., Haddad P.S. Antioxidant and hepatoprotective effects of silibininin a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med. 2011; 2011:nep164. doi: 10.1093/ecam/nep164.